首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1812457

內分泌治療市場按治療領域、給藥途徑、年齡層、分銷管道、最終用戶和地區分類

Endocrinology Drug Market, By Therapy Area, By Route of Administration, By Age Group, By Distribution Channel, By End User, By Geography

出版日期: 2025年08月20日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

內分泌治療市場規模預計在 2025 年達到 741.1 億美元，預計在 2032 年達到 995.1 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 4.3%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	741.1億美元
效能數據	2020年至2024年	預測期	2020年至2024年
預測期：2025-2032年複合年成長率：	4.30%	2032年的價值預測	995.1億美元

全球內分泌治療市場是治療荷爾蒙和代謝失調的重要領域，這些失調影響著全球數百萬人。內分泌學涵蓋荷爾蒙分泌腺體及其相關疾病的研究，包括糖尿病、甲狀腺功能障礙、生長激素缺乏症、骨質疏鬆症、肥胖症和生殖激素失衡。在生物技術、個人化醫療方法和創新藥物傳輸系統的推動下，該領域的藥物正在經歷重大變化。

現代內分泌治療藥物涵蓋多種類別，包括胰島素類似物、GLP-1受體促效劑、SGLT-2抑制劑、甲狀腺激素替代藥物、雙磷酸鹽和荷爾蒙補充療法。市場複雜性源自於患者族群多樣化，需要客製化治療方法，涵蓋從兒童生長遲緩到老年代謝疾病等各種疾病。持續血糖監測、智慧胰島素輸送系統和生物標記主導診斷領域的技術創新正在徹底改變治療模式，並推動精準醫療方法的發展。此外，與生活方式相關的內分泌疾病（尤其是糖尿病和肥胖症）的盛行率日益上升，推動了研究投入和監管重點的增加，以開發療效更佳、副作用更少的下一代療法。

市場動態

全球內分泌治療市場正經歷強勁成長，這得益於多種相互關聯的因素。一個關鍵的市場驅動力是全球糖尿病盛行率的上升，目前糖尿病影響著超過5億人，對創新的血糖管理解決方案、胰島素療法和聯合治療的需求龐大。人口老化是市場擴張的主要原因，因為老年人口更容易患甲狀腺疾病、骨質疏鬆症和荷爾蒙失衡，需要長期藥物介入。藥物製劑的技術進步，例如緩釋性機制、生物相似藥開發和新型給藥系統，正在推動市場創新，同時提高患者的依從性和治療效果。

然而，市場發展面臨著巨大的限制，包括嚴格的監管核准流程，這延遲了產品的上市，並增加了開發成本，尤其是對於複雜的生技藥品和聯合治療。重磅內分泌治療藥物的專利到期，給原研公司帶來了定價壓力，並侵蝕了市場佔有率，而醫療成本控制措施則影響了全球的報銷政策和藥物的可及性。

此外，生物製藥的生產複雜性、供應鏈脆弱性和品管要求也帶來了營運挑戰。即便如此，新興經濟體中尚未開發的市場仍可能蘊藏著巨大的商機。這些市場的糖尿病和代謝性疾病病例正在迅速增加，但治療滲透率卻較低。利用基因檢測和生物標記識別的個人化醫療方法為標靶治療帶來了豐厚的前景。包括遠端醫療平台和人工智慧驅動的治療最佳化在內的數位健康整合正在創造新的收益來源並增強病人參與，使內分泌治療市場在面臨挑戰的情況下仍能保持持續成長。

本次調查的主要特點

本報告對全球內分泌治療市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它強調了各個領域的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球內分泌治療市場的主要企業。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。
本報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球內分泌治療市場的各種策略矩陣更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 74.11 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	4.30%	2032 Value Projection:	USD 99.51 Bn

The global endocrinology drug market represents a critical therapeutic segment addressing hormonal disorders and metabolic diseases that affect millions worldwide. Endocrinology encompasses the study of hormone-producing glands and their associated disorders, including diabetes mellitus, thyroid dysfunction, growth hormone deficiencies, osteoporosis, obesity, and reproductive hormone imbalances. The pharmaceutical landscape within this domain has witnessed remarkable evolution, driven by advancing biotechnology, personalized medicine approaches, and innovative drug delivery systems.

Modern endocrinology therapeutics span across various drug classes including insulin analogues, GLP-1 receptor agonists, SGLT-2 inhibitors, thyroid hormone replacements, bisphosphonates, and hormone replacement therapies. The market's complexity stems from diverse patient populations requiring tailored treatment regimens, ranging from pediatric growth disorders to geriatric metabolic conditions. Technological breakthroughs in continuous glucose monitoring, smart insulin delivery systems, and biomarker-driven diagnostics have revolutionized treatment paradigms, enabling precision medicine approaches. Additionally, the growing prevalence of lifestyle-related endocrine disorders, particularly diabetes and obesity, has intensified research investments and regulatory focus on developing next-generation therapeutics with improved efficacy profiles and reduced adverse effects.

Market Dynamics

The global endocrinology drug market experiences robust growth driven by multiple interconnected factors that shape its trajectory. Primary market drivers include the escalating prevalence of diabetes worldwide, with over 500 million affected individuals creating substantial demand for innovative glucose management solutions, insulin therapies, and combination treatments. Aging demographics contribute significantly to market expansion as elderly populations exhibit higher susceptibility to thyroid disorders, osteoporosis, and hormonal imbalances requiring long-term pharmaceutical interventions. Technological advancements in drug formulation, including extended-release mechanisms, biosimilar development, and novel delivery systems, drive market innovation while improving patient compliance and therapeutic outcomes.

However, the market growth faces considerable restraints including stringent regulatory approval processes that delay product launches and increase development costs, particularly for complex biologics and combination therapies. Patent expirations of blockbuster endocrinology drugs create pricing pressures and market share erosion for originator companies, while healthcare cost containment measures globally impact reimbursement policies and accessibility.

Additionally, manufacturing complexities associated with biologic drugs, supply chain vulnerabilities, and quality control requirements pose operational challenges. Nevertheless, significant opportunities emerge through untapped markets in developing economies where diabetes and metabolic disorders are rapidly increasing but treatment penetration remains low. Personalized medicine approaches leveraging genetic testing and biomarker identification present lucrative prospects for targeted therapeutics. Digital health integration, including telemedicine platforms and AI-driven treatment optimization, creates new revenue streams and enhances patient engagement, positioning the endocrinology drug market for sustained growth despite existing challenges.

Key features of the study

This report provides in-depth analysis of the global endocrinology drug market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global endocrinology drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Pfizer Inc, Merck & Co Inc, Novartis AG, AstraZeneca plc, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Ipsen Pharma, Teva Pharmaceutical Industries Ltd, Amgen Inc, and Bayer AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global endocrinology drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global endocrinology drug market

Market Segmentation

Therapy Area Insights (Revenue, USD Bn, 2020 - 2032)
- Diabetes Management Drugs
- Insulin (short-acting, long-acting, and premixed)
- Oral Antidiabetics (biguanides, sulfonylureas, thiazolidinediones, etc.)
- GLP-1 Receptor Agonists
- Other Combination Therapies
- Thyroid Disorder Drugs
- Hypothyroidism Treatments (levothyroxine and liothyronine)
- Hyperthyroidism Treatments (antithyroid drugs and radioiodine therapy adjuncts)
- Growth Hormone Related Drugs
- Growth Hormone Deficiency Treatments (recombinant growth hormones, etc.)
- Acromegaly Treatments (somatostatin analogs, GH receptor antagonists, etc.)
- Adrenal Disorder Drugs
- Cushing's Syndrome Treatments (steroidogenesis inhibitors, pituitary-targeted drugs)
- Addison's Disease Treatments (glucocorticoids and mineralocorticoids)
- Congenital Adrenal Hyperplasia Drugs
- Reproductive Endocrinology Drugs
- Men's Health (testosterone therapies and anti-androgens)
- Women's Health (estrogen therapies, progesterone therapies, etc.)
- Fertility Drugs (gonadotropins, ovulation stimulants, etc.)
- Calcium and Bone Metabolism Drugs
- Osteoporosis Treatments (bisphosphonates, SERMs, calcitonin, etc.)
- Hyperparathyroidism Treatments (calcimimetics, vitamin D analogs, etc.)
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Transdermal (patches and gels)
- Nasal
- Others (e.g., sublingual, rectal)
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Clinics
- Specialty Endocrine Centers
- Ambulatory Surgical Centers (ASCs)
- Homecare Settings
- Others (Academic and Research Institutes, etc.)
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- Pfizer Inc
- Merck & Co Inc
- Novartis AG
- AstraZeneca plc
- AbbVie Inc
- Takeda Pharmaceutical Company Limited
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd
- Amgen Inc
- Bayer AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Endocrinology Drug Market, By Therapy Area
- Global Endocrinology Drug Market, By Route of Administration
- Global Endocrinology Drug Market, By Age Group
- Global Endocrinology Drug Market, By Distribution Channel
- Global Endocrinology Drug Market, By End User
- Global Endocrinology Drug Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Endocrinology Drug Market, By Therapy Area, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Diabetes Management Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Insulin (short-acting, long-acting and premixed)
  - Oral Antidiabetics (biguanides, sulfonylureas, thiazolidinediones, etc.)
  - GLP-1 Receptor Agonists
  - Other Combination Therapies
Thyroid Disorder Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Hypothyroidism Treatments (levothyroxine and liothyronine)
  - Hyperthyroidism Treatments (antithyroid drugs and radioiodine therapy adjuncts)
Growth Hormone Related Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Growth Hormone Deficiency Treatments (recombinant growth hormones, etc.)
  - Acromegaly Treatments (somatostatin analogs, GH receptor antagonists, etc.)
Adrenal Disorder Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Cushing's Syndrome Treatments (steroidogenesis inhibitors, pituitary-targeted drugs)
  - Addison's Disease Treatments (glucocorticoids, mineralocorticoids)
  - Congenital Adrenal Hyperplasia Drugs
Reproductive Endocrinology Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Men's Health (testosterone therapies and anti-androgens)
  - Women's Health (estrogen therapies, progesterone therapies, etc.)
  - Fertility Drugs (gonadotropins, ovulation stimulants, etc.)
Calcium and Bone Metabolism Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Osteoporosis Treatments (bisphosphonates, SERMs, calcitonin, etc.)
  - Hyperparathyroidism Treatments (calcimimetics, vitamin D analogs, etc.)

5. Global Endocrinology Drug Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Transdermal (patches and gels)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (e.g., sublingual and rectal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Endocrinology Drug Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Endocrinology Drug Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Endocrinology Drug Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Endocrine Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Endocrinology Drug Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Therapy Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

11. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

12. References and Research Methodology

References
Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

內分泌藥物市場按治療領域、藥物類別、給藥方式、患者年齡層和分銷管道分類－2025-2030 年全球預測

紅斑肢體疼痛治療市場按類型、應用、給藥途徑、藥物、通路和地區分類

5α 還原酶缺乏症市場：按類型、最終用戶、年齡層、診斷方法、治療 - 全球預測 2025-2030

罕見內分泌疾病治療的全球市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按適應症、按藥物類型、按給藥方式、按分銷管道、按地區

到 2030 年內分泌治療的市場預測：按治療領域、配銷通路、給藥途徑、最終用戶和地區進行的全球分析

FAQ

內分泌治療市場按治療領域、給藥途徑、年齡層、分銷管道、最終用戶和地區分類

Endocrinology Drug Market, By Therapy Area, By Route of Administration, By Age Group, By Distribution Channel, By End User, By Geography

市場動態

目錄

第 1 章：調查目標與先決條件

第2章市場展望

第3章：市場動態、法規與趨勢分析

4. 2020-2032 年全球內分泌治療市場（依治療領域）

5. 2020-2032 年全球內分泌治療市場（依給藥途徑）

6. 2020-2032 年全球內分泌治療市場（依年齡層）

7. 2020-2032 年全球內分泌治療市場（依通路）

8. 2020-2032 年全球內分泌治療市場（依最終使用者分類）

9. 2020-2032 年全球內分泌治療市場（按地區）

第10章競爭格局

第 11 章分析師建議

第12章參考文獻與調查方法